MYM Website  |  About  |  Operations  |  I.R.                                                     Get FinancialNewsMedia.com Alerts 

Privacy Policy

MYM Nutraceuticals Inc. (OTCQB: MYMMF) (CSE: MYM.CN) News - January 24, 2018

 


MYM Responds to Recent News out of the United States and Provides Global Operations Update


Vancouver, B.C., Jan. 24, 2018 – In response to recent news out of the United States Department of Justice regarding federal cannabis laws in the United States, MYM Nutraceuticals Inc., (OTCQB: MYMMF) (CSE: MYM) (the “Company” or “MYM”) wishes to reinforce its commitment to growing and conducting business only in jurisdictions where that conduct is federally legal and otherwise in full compliance with all applicable laws in place.

MYM does not currently have any operations in the United States and will not engage in that country unless significant changes to the federal laws regarding cannabis are made. This stance is to protect the company and its shareholders.

MYM Nutraceuticals is an international company, with operations in Australia, Canada, and most recently seeking operations in Colombia. We are pleased with our progress on each of our global operations and the prospects they bring.

Because our operations hold significant potential, and are in favorable business jurisdictions, MYM is privileged to have options when it comes to financing our current and future projects and operations. We are currently exploring all options that bring the least amount of dilution to our shareholders.

As an unintended benefit of not conducting operations in the United States, MYM has been presented with multiple options from financiers looking for safe havens for their investments. However, we continue to build business relationships throughout the United States in anticipation of any changes that lead to the opening of the country for business. Should those changes be made, MYM is ready and prepared to initiate legal operations in the USA.

QUEBEC, CANADA
MYM Nutraceuticals and its subsidiary, Sublime Culture Inc., were pleased with the December 15th, 2018 completion of Phase One of construction on the Sublime facility in Laval, Québec. Upon this completion, MYM submitted the required Confirmation of Readiness for a License under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to Health Canada for the facility.

MYM further bolstered the facility’s breeding capabilities by contracting the services of Master Breeder Sasha Przytyk. Going forward, Mr. Pyztyk will be responsible for developing a comprehensive cannabis seed breeding and production program for Sublime Culture and MYM. Master Breeder Sasha Przytyk specializes in improving and enhancing the genetics of cannabis strains. These improvements include more production, faster growing, higher or lower levels of THC, improved terpenes, climate resistance and many other positive improvements. My Przytyk will also be responsible for the creation of MYM’s own proprietary genetic strains and seeds.

We are confident in our selection of the province of Québec for our flagship project at Weedon, Québec, and for the Laval facility. We have received significant support from local governments, and assurances that our facilities will be welcome in the province going forward.

Recently, the province-owned power provider Hydro-Québec extended its preferential electricity rates for cannabis producers, giving us and other cannabis firms an advantage over other provinces, and making Québec a very desirable place to do business.

Whether it be on our newly completed Laval facility of 10,000 sf, or on our massive 1.5 million sf project in Weedon, Québec, we see the province as a very friendly jurisdiction for our business model going forward.

NEW SOUTH WALES, AUSTRALIA
MYM, along with its partners, maintain that Australia is an exciting new market, having recently legalized medicinal cannabis. Much like our 1.5 million sf facility in Weedon, Québec, our joint-venture Solaris facility will also be massive, at a projected 1.2 million sf in growing space.

Australia has recently announced that as of February 2018, the country will begin to allow the worldwide export of cannabis-based treatments such as oils, patches, sprays, lozenges, and tablets.

With our partners, we formed the joint venture company, Solaris Nutraceuticals. Together, Solaris is currently in the assessment phase of the licensing process to build the 1.2 million sf greenhouse facility, which will be the largest cannabis production facility in Australia. We expect that export of cannabis products from Australia will be big business and could possibly outpace domestic sales.

COLOMBIAN OPPORTUNITY
In continuity with our global strategy, MYM recently signed a MOU with NEWCANNA S.A.S., a leading Colombian medical cannabis company to form a new joint-venture company. We saw this is as a massive opportunity for large-scale commercial cannabis cultivation and transformation of cannabis and hemp for medical, scientific and industrial purposes and export to global markets.

NEWCANNA brings with it agreements that represent a total of 7,400 acres of cultivation property. Growers over those properties have the capacity to be producing high-grade cannabis at low cost, for processing and export worldwide.

In partnership with the indigenous farmers of Colombia, NEWCANNA projects a substantial opportunity to increase the current output of cannabis. The high mountains of Colombia provide a perfect climate to cultivate cannabis and allow production costs to be a fraction of what it costs to produce in Canada.

The biggest value-added proposition of the deal is in the cultivation and transformation of raw materials into medicinal oils, tinctures and a variety of products.

Much like our projects in Québec and Australia, the Colombian plan also includes a significant commitment to research and development for new products and enhancements to our lines.

BRANDING AND MARKETING
Beyond our growing facilities in Australia, Canada, and Colombia, MYM has maintained growth through our brands and other properties.

We recently acquired Budly, an Uber-like delivery system for cannabis, which is a smartphone-enabled sales and distribution system connecting medical cannabis patients with local dispensary drivers for fast delivery and monitoring of orders. We believe that distribution will be a significant aspect of the cannabis market upon official legalization, and we were pleased to acquire a leading player in that section of the market.

Next, we’ve been quite pleased with our acquisition of the Joshua Tree brand, which we acquired last spring. Since becoming part of the MYM asset portfolio, Joshua Tree has enjoyed sales increases of 850% in just 10 months.

As we move forward with our facilities in Australia, Canada, and Colombia, we anticipate many more strains, products, and brands to come for MYM.

GOING FORWARD
To reiterate, MYM does not and will not conduct business in any jurisdiction unless it is federally permissible. Conducting activities which are federally illegal or investing in companies which do, would expose our company to increased risk of prosecution and/or delisting from exchanges. Such activities would also compromise MYM’s ability to operate freely and could jeopardize our listing eligibility on major securities exchanges now and in the future, and limit access to capital from reputable US-based funds and world-class partners.

“Because of our independence from the US market, we have received an array of options from international funds, including from the United States. There is an appetite for investment in our sector that gives us confidence we have will see each of our large projects through to fruition,” said Rob Gietl, CEO of MYM. “We will fully vet each of our options, and select only those that will minimize or eliminate any dilution for our shareholders.”

About MYM Nutraceuticals Inc.
MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a partner in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc
www.mymarijuana.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.
This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.
This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations
Terry Brown
+1-855-696-2261
terry@mymarijuana.ca

Keep up to date with MYM on our social media channels:
Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra

SOURCE MYM Nutraceuticals Inc.

 

MYM Signs MoU With Colombian Medical Cannabis Company NEWCANNA


Vancouver, B.C., Jan. 22, 2018 – MYM Nutraceuticals Inc., (OTCQB: MYMMF) (CSE: MYM) (the “Company” or “MYM”) is pleased to announce it has signed a Memorandum of Understanding (MoU) with NEWCANNA S.A.S., a leading Colombian medical cannabis company.

MYM and NEWCANNA are proposing a joint venture or partnership agreement in which they would form a new, jointly owned company in Colombia. This partnership would focus on the large-scale commercial cultivation and transformation of cannabis and hemp for medical, scientific and industrial purposes and export to worldwide markets.

NEWCANNA has agreements in place with multiple indigenous communities in Colombia totaling over 400 families (approx. 1,400 people) that control 7,400 acres of cultivation property. In 2018 the indigenous growers have the capacity to be producing approximately 217,500 kg of high-grade cannabis for processing and export worldwide. With planned production expansion with the indigenous growers, NEWCANNA's production is expected to be over 1,000,000 kg of cannabis in a year or two. The high mountains of Colombia provide a perfect climate to cultivate cannabis and allow production costs to be a fraction of what it costs to produce in Canada.

MYM and NEWCANNA are also proposing that, along with the cultivation and transformation of raw materials into medicinal oils, tinctures and a variety of products, they also construct a research and development laboratory for the design and creation of new products, in-house analysis and testing, and the refinement of new and unique delivery systems.

In the last year, NEWCANNA has consolidated vast properties of land that are ideal for the cultivation of cannabis and hemp throughout different regions of Colombia. NEWCANNA has formed valuable alliances with multiple indigenous communities within Colombia and has a large workforce of eager participants for all planned organic cultivation projects.

"This is a tremendous opportunity and another big step towards MYM's stated goal of becoming a global cannabis player," said Rob Gietl, CEO of MYM. "NEWCANNA has the infrastructure in place to dominate the Colombian cannabis markets both domestically and for exportation to the rest of the world. NEWCANNA's commitment to working with the indigenous population of Colombia satisfies MYM's position to work with local communities and provides economic benefits to local inhabitants."

Under the MoU, NEWCANNA will supply the land, the workforce, and all the applicable licenses needed for the new company to move forward and operate legally under the newly established laws in Colombia. The new company will have the opportunity to become part of the NEWCANNA HUB, a group of unique companies dedicated to the research, education and sustainability for the commercial future of cannabis in Colombia. The members and alliances of the HUB come from a wide variety of backgrounds surrounding the legalities of cultivation, production, transformation, and the ongoing studies of cannabis, cannabinoids, and the endocannabinoid system in humans and animals.

MYM has retained the Colombian law firm Dentons Cardenas & Cardenas Abogados Ltda. to represent MYM's interests in Colombia moving ahead with the NEWCANNA MoU. There can be no assurance that the transaction contemplated by the MoU will be successfully completed. See the cautionary note regarding forward-looking statements below.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space. MYM is also a partner in a 1.2 million square-foot production project (the Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).

ON BEHALF OF THE BOARD

Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results, including with respect to the MoU and the transaction contemplated thereby (the "Transaction") and the Company's plans, objectives and expected outcomes. In making the forward-looking statements, the Company has applied several material assumptions including, but not limited to, the assumptions that: definitive Transaction agreements will be entered into and the Transaction will proceed and be completed as planned, the expected benefits from the Transaction will be achieved and required regulatory approvals will be obtained. These forward-looking statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others and in addition to those described elsewhere in this release, inability to obtain regulatory approvals of the Transaction, inability to complete the Transaction on the proposed terms or at all, that the Transaction, if completed, will not result in the expected benefits to the Company, inability to achieve desired outcomes and delays in obtaining or inability to obtain required government or other regulatory approvals. The Company disclaims any intention or obligation to revise or update such statements, except as required by applicable securities legislation. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations
Terry Brown
+1-855-696-2261
terry@mymarijuana.ca

Keep up to date with MYM on our social media channels:
Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra

SOURCE MYM Nutraceuticals Inc.

 

MYM and Sublime Sign Consulting Agreement With Master Breeder Sasha Przytyk


Vancouver, B.C., Jan. 18, 2018 – MYM Nutraceuticals Inc., (OTCQB: MYMMF) (CSE: MYM) (the “Company” or “MYM”) is pleased to announce that it and its subsidiary, Sublime Culture Inc., have entered into a consulting agreement with Sasha Przytyk, who will act as Master Breeder at the Sublime facility in Laval, Québec.

As Master Breeder, Mr. Przytyk will be responsible for developing a comprehensive Cannabis seed breeding and production program for Sublime Culture and MYM. His initial focus will be to search out and select source seed varieties from breeders and reputable international seed houses. In parallel, Sasha will design and conduct an ongoing research program, to evaluate and analyze seed strains under varying conditions. In the long term, Sasha promises to create improved, proprietary varieties through selection and hybridization, to supply the Canadian and international cannabis seed market.

Sasha has extensive experience in the medicinal cannabis and horticultural sector. He is a designated cannabis grower, licensed through Health Canada's MMAR and AMCPR programs since 2009. Sasha was the first private recipient of a Health Canada Industrial Hemp Research license in Québec. He is currently the owner of a cannabis seed brand-management company, Shazam Farms International Inc.

Sasha has extensive experience as a guest speaker and delegate at international cannabis conferences and symposiums. He is also an accomplished publisher in the field, writing numerous articles on hemp and its cultivation.

Sasha established 'The Joint Doctor' and 'High-Bred Seeds' as world-renowned seed brands. Through the revolutionary strain 'Lowryder,' he introduced the concept of autoflowering cannabis. Lowryder is recognized worldwide as the first 100% autoflowering variety and The Joint Doctor has been dubbed the 'Father of Autoflowering.' Widely adopted by seed companies today, autoflowering strains now represent approximately 40% of the European seed market.

"We are thrilled to welcome Sasha to the MYM team as Master Breeder. His experience in the hemp, cannabis, and horticultural industry is unparalleled," said Rob Gietl, MYM's CEO. "Sasha's innovation in seed technology will prove to be a valuable asset to the shareholders of MYM as growing cannabis becomes increasingly accepted and adopted around the world."

Pursuant to the five-year consulting agreement, which is with Mr. Przytyk's company, Shazam Farms, Sasha will receive a signing bonus of $25,000, paid in 7,062 MYM common shares at a deemed price per share of $3.54.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space. MYM is also a partner in a 1.2 million square-foot production project (the Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).

On Behalf of the Board
Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States.The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the 'U.S. Securities Act'), or any state securities law and may not be offered or sold in the 'United States', as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations
Terry Brown
+1-855-696-2261
terry@mymarijuana.ca

Keep up-to-date with MYM on our social media channels:
Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra

https://c212.net/c/img/favicon.png?sn=IO91542&sd=2018-01-18 View original content:http://www.prnewswire.com/news-releases/mym-and-sublime-sign-consulting-agreement-with-master-breeder-sasha-przytyk-300584434.html

SOURCE MYM Nutraceuticals Inc.

 

MYM Acquires Budly, the 'Uber of Cannabis'


Vancouver, B.C., Jan. 5, 2018 – MYM Nutraceuticals Inc., (OTCQB: MYMMF) (CSE: MYM) (the “Company” or “MYM”) is pleased to announce that the Company has entered into a binding letter of intent with Budly Software Inc. ("Budly"), a leading software company that has developed a smartphone-enabled sales and distribution system connecting medicinal cannabis patients with local dispensary drivers for fast delivery and monitoring of orders. Using the system, a customer can select a dispensary, place an order, and then choose a driver to deliver it. The customer can then track the order on his smartphone and knows exactly when it will arrive. Orders can be placed via the Budly app on iOS, Android and Windows phones, and via the website www.budly.com.

"The Budly software is a game-changer for MYM because it brings us one step closer to becoming a fully integrated global cannabis company," commented Rob Gietl, CEO of MYM. "Budly's clean and simple interface allows orders to be easily placed by patients, right on their phone, and provides extensive back end management and logistics control for licensed producers and dispensaries."

The Budly system consists of two iOS apps, two Android apps, one web app, a dispensary backend admin and a master admin system. The system also has advanced features such as GPS tracking of drivers, flexible geo-fencing adjustments for customers, and real-time order confirmations. MYM intends to add more features and functions to the Budly system in the near future, and to launch Budly globally as more jurisdictions legalize cannabis. The Budly system can easily be customized for the individual requirements and regulations for different countries and regions.

Pursuant to the letter of intent, MYM will issue 800,000 common shares to Budly in exchange for all non-U.S. rights to Budly's software and intellectual property. Should federal legislation change in the States, MYM will have first right of refusal for the rights in that country. The completion of the transaction is subject to the approval of the Canadian Securities Exchange.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space. MYM is also a partner in a 1.2 million square-foot production project (the Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

About Budly Software Inc.

Budly is the modern way for medicinal cannabis patients to get their medication quickly, safely and easily. Budly is a mobile application that enables patients to order medicinal cannabis from their local dispensary. Simply choose a dispensary, place an order, then choose a driver. Accept the order and the countdown clock starts, letting the customer know when the order will arrive. Learn more at www.budly.com.

ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

Keep up to date with MYM on our social media channels:
Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer's future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

Investor Relations
Terry Brown
+1-855-696-2261
terry@mymarijuana.ca

SOURCE MYM Nutraceuticals Inc.

 

MYM Announces $10 Million Non-brokered Financing


Vancouver, B.C., Jan. 3, 2018 – MYM Nutraceuticals Inc., (OTCQB: MYMMF) (CSE: MYM) (the “Company” or “MYM”) is pleased to announce a non-brokered private placement of up to 3,571,000 units at a price of CAD$2.80 per unit.

Each unit will consist of one common share and one transferable common share purchase warrant. Each warrant will entitle the holder to acquire one additional common share for a period of 24 months following the closing of the private placement at a price of CAD$4.00 per warrant share.

In the event that, after the date that is six months and one day following the closing of the offering, the closing volume-weighted average price of the common shares on the Canadian Securities Exchange, or such other exchange on which the common shares may primarily trade, is greater than or equal to CAD$5.50 for a period of ten consecutive trading days, the Company may, at its sole option, accelerate the expiry date of the warrants by giving notice to the holders thereof, and in such case, the warrants will expire on the 30th day after the date on which such notice is given by the Company.

The offering was priced in the context of the market based on a price reservation made by the Company with the Canadian Securities Exchange. The private placement is subject to the approval of the CSE and the securities will be subject to a four-month hold period under securities laws. The Company intends to use the net proceeds from the private placement for general working capital and corporate purposes.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM has two production projects in Québec that when completed will have over 1.5 million square feet of production space. MYM is also a partner in a 1.2 million square-foot production project (the Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results, including with respect to a non-brokered private placement (the "Offering") and the use of proceeds therefrom. In making the forward-looking statements, the Company has applied several material assumptions including, but not limited to, the assumptions that: the Offering will proceed and be completed as planned and required regulatory approvals will be obtained. These forward-looking statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others and in addition to those described elsewhere in this release, inability to obtain regulatory approvals of the Offering, inability to complete the Offering on the proposed terms or at all and delays in obtaining or inability to obtain required government or other regulatory approvals. The Company disclaims any intention or obligation to revise or update such statements, except as required by applicable securities legislation. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on http://www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Market Regulator (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

ON BEHALF OF THE BOARD
Rob Gietl, CEO
MYM Nutraceuticals Inc.
http://www.mymarijuana.ca

Keep up to date with MYM on our social media channels:

Twitter: @MYM_Nutra
Facebook: @mymcanada
Instagram: @MYM_Nutra

SOURCE MYM Nutraceuticals Inc.

 

-------------------------------------------------------------------
About MYM Nutraceuticals Inc.:


LOOKING BEYOND THE TOMORROW TO ENVISION AND CRAFT A NEW INDUSTRY
Building a brand new industry is no small feat to be taken lightly. Our team of visionaries have an unbeatable track record of successful startups and have extensive experience in emerging markets. The MYM Nutraceuticals team is building a foundation in the medical marijuana sector that will set the company apart from its competitors with a focus on marijuana growing technology, perfecting our brands and distribution strategies.

- What does the market want?
- Where will the market go?
- What does it look like in 10 years?
- What other businesses will benefit?
- How can we enter the USA market
- What does distribution look like?
- How can we innovate?
- How will legalization change everything?
- What can we learn from prohibition?
- How can we leverage partnerships?
- What is the best way to educate our customers?
- What are our goals for research and development?
- What other products can we develop?
- What will set our brands apart from others?
- How can we do it better?

While many companies are now just trying to answer these questions, the MYM Nutraceuticals team for the past 9 years has been working on the answers and creating solutions. Nine years of research, analytics, brain storming, field experience and market research has resulted in a unified company vision that will build a company unlike any other in the industry. Through innovation, advanced distribution and creative marketing MYM Nutraceuticals is leading the charge of this exciting new industry.

MYM Nutraceuticals Inc. is an emerging bio-pharmaceutical company and distributor of medical marijuana products that has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations. MYM Nutraceuticals has an extensive list of industry assets that make it well prepared for commercial distribution of medical marijuana, including a growing facility property, exclusive access to patients and many years of industry expertise on the company’s board of directors and staff.

Licensed Production |

We are currently in the application process in Canada and the USA for medical marijuana

Growing Technology |

Our team has over 30 years of growing experience to create higher quality products.

Brand Marketing |

We are reinventing current branding & marketing strategies within legalized Marijuana.

Distribution |

We are using technology to build out innovative distribution systems and networks.

What We Do HomeWhat We Do
MYM Nutraceuticals is focused on building and/or acquiring and growing businesses in the Marijuana sector.

These are our business divisions:

MYM Nutraceuticals

MYM Nutraceuticals – This is the umbrella corporation that will look to invest and develop its own brands as well as capitalize
on other established brands once we have secured our Health Canada license for cannabis production. MYM will use the
knowledge and experience of its management team to create new brands and bring in assets that will help the company grow rapidly

Sublime growers
Sublime – This newly acquired company will facilitate the production and distribution of cannabis products initially through production in a 10,000 SF
facility located in the Montreal area with further expansion to 36,000 SF within the next 18-24 months. Sublime has progressed to the final
two stages of the production licensing application process of the ACMPR. A final inspection is set for August 2017. This brand
will offer high end Indica and Sativa Cannabis products for sale to our patients as well as high end Co2 extracted oils (concentrates).

HempMed CBD

HempMed – This Line features our most advanced line of cannabis products. These are tailored products that combine just the right amounts of CBD for specific ailments. Whether it’s pain relief, calming seizures, relieving the symptoms of Crones disease or aiding in the recovery of Chemotherapy treatments, this product line will change the lives of people fed up with harmful pharmaceutical products.

MyHemp

My Hemp – This brand will lay the foundation for our life style products by establishing our brand as a true household
name. We are creating unique products into a rapidly growing marketplace that appeal to both men and women.

Our Team

CEO, Rob Gietl
Mr. Gietl is well known for his ability to exponentially grow businesses including the west-coast franchise expansion of Domino’s Pizza, where he consistently grew the annual business to achieve 300+% increases year-over-year.
Mr. Gietl is a seasoned Business Development and Operations executive with a diverse track record of leading change across all areas of concept creation, brand re-positioning, market penetration, fiscal accountability and efficient execution of business plans. He has grown business effectiveness in an array of sectors and circumstances throughout Canada, consistently aligned with stakeholders’ goals and values

Mr. Gietl is a seasoned Business Development and Operations executive with a diverse track record of leading change across all areas of concept creation, brand re-positioning, market penetration, fiscal accountability and efficient execution of business plans. He has grown business effectiveness in an array of sectors and circumstances throughout Canada, consistently aligned with stakeholders goals and values.

Director of Operations, Jonathan Fiteni
Jonathan Fiteni has over 14 years of experience in the medical marijuana industry in general, and in product development and construction of marijuana facilities in particular. Mr. Fiteni is very educated and experienced in producing medical quality marijuana strains from seed to patient. He has designed and managed the building of numerous high-density growing facilities, requiring stringent construction standards. Using hydroponics and other sophisticated growing methods, he has successfully integrated complex electrical, dehumidification, HVAC and irrigation systems together to produce high quality organic marijuana products.

Director, Ian Ramage
Ian Ramage holds a B.A.Sc. in Computer Engineering from Simon Fraser University and J.D. and LL.M. degrees from the University of British Columbia. He practiced law in the Bay Area for eight years for a variety of biotech and high-tech clients before returning to Vancouver in 2009 to continue to build his corporate and securities practice. Mr. Ramage is an expert in Canadian and U.S securities and corporate law; copyright and trademark acquisition and enforcement; patent, copyright, and trade secret litigation.

Chief Financial Officer, Mark Forster
Mark Forster will be responsible for the preparation of financial statements, continuing disclosure of the Resulting Issuer and the management of internal control procedures. He has over 25 years of financial accounting experience in banking, manufacturing of beer, wine, and spirits, the oil and gas industry and in the mining sector. He has been a director and the CFO of Teletouch Services Inc., a private technology company, since December 2004. He was a manager of Bearingpoint LLP, a management and technology company, from January 1996 to December 2006. Mark G. Forster was granted a CGA designation by the Certified General Accountant’s Association, BC in 1992.

Investor Relations

MYM Investor Relations Contact info:
Terry Brown
Tel: 1-855-696-2261

You can email Mr. Brown here: http://www.mymarijuana.ca/contact-us/

MYM Nutraceuticals Inc. CSE:MYM OTC:MYMMF FRA:0MY, is a bio-pharmaceutical company focused on production, distribution, innovation, technology and branded products related to the Marijuana industry. Our executive team has built numerous successful companies from the ground up and are striving to make MYM a world class brand.

The MYM Nutraceuticals team has been working in the medical marijuana industry for many years and now that the Canadian and USA markets are starting to open up, they are putting their vast experience to work. The company is leveraging the teams extensive and successful business experience to innovate this brand new exciting industry. The rapid and expansive growth predicted for the industry is staggering and we believe that our visionary team have the background and motivation for MYM Nutraceuticals to become the market leader.

SOURCE: http://mymarijuana.ca/




Disclaimer

FN Media Group LLC (FNMG) owns and operates FinancialNewsMedia.com (FNM) which is a third party publisher that disseminates electronic information through multiple online media channels. FNMG's intended purposes are to deliver market updates and news alerts issued from private and publicly trading companies as well as providing coverage and increased awareness for companies that issue press to the public via online newswires. FNMG and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. The companies that are discussed in this release may or may not have approved the statements made in this release. Information in this release is derived from a variety of sources that may or may not include the referenced company's publicly disseminated information. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. While this information is believed to be reliable, such reliability cannot be guaranteed. FNMG disclaims any and all liability as to the completeness or accuracy of the information contained and any omissions of material fact in this release. This release may contain technical inaccuracies or typographical errors. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. Investment in the securities of the companies discussed in this release is highly speculative and carries a high degree of risk. FNMG is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. This release is not without bias, and is considered a conflict of interest if compensation has been received by FNMG for its dissemination. To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always disclose any compensation it has received, or expects to receive in the future, for the dissemination of the information found herein on behalf of one or more of the companies mentioned in this release. For current services performed FNMG has been compensated forty nine hundred dollars for MYM Nutraceuticals Inc. coverage by a non affiliated third party.  FNMG HOLDS NO SHARES OF MYM Nutraceuticals Inc.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.